A Case of Elevated Prothrombin Time-International Normalized Ratio (PT-INR) Associated with Concurrent Use of Erlotinib and Warfarin |
Kim, Seung-Kyoung
(Department of Internal Medicine, St. Mary’s Hospital, The Catholic University of Korea School of Medicine)
Park, Kyung-Seon (Department of Internal Medicine, St. Mary’s Hospital, The Catholic University of Korea School of Medicine) Choi, Seung-Hwa (Department of Internal Medicine, St. Mary’s Hospital, The Catholic University of Korea School of Medicine) Byun, Jae-Ho (Department of Internal Medicine, St. Mary’s Hospital, The Catholic University of Korea School of Medicine) Woo, In-Sook (Department of Internal Medicine, St. Mary’s Hospital, The Catholic University of Korea School of Medicine) Han, Chi-Hwa (Department of Internal Medicine, St. Mary’s Hospital, The Catholic University of Korea School of Medicine) Kim, Hyo-Lim (Department of Radiology, St. Mary’s Hospital, The Catholic University of Korea School of Medicine) |
1 | Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. DOI ScienceOn |
2 | Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatments, and survivorship. Mayo Clin Proc 2008;83:584-594. DOI |
3 | Korean National Statistical Office. The cause of death statistics, Daejeon: Korean National statistical office, c2006. [cited 2010, March 10]. Available from: http://www.Cancer.go.kr/cms/statics/mortality/index.html. |
4 | Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet 2005;366:1527-1537. DOI ScienceOn |
5 | Arai S, Mitsufuji H, Nishii Y, et al. Effect of gefitinib on warfarin antithrombotic activity. Int J Clin Oncol 2009;14:332-336. DOI ScienceOn |
6 | Onoda S, Mitsufuji H, Yanase N, et al. Drug interaction between gefitinib and warfarin. Jpn J Clin Oncol 2005;35:478-482. DOI ScienceOn |
7 | Micromedex Products. Erlotinib. [cited 2010. March 10]. Available from: http://www.thomsonhc.com/ hcs/ librarian. |
8 | Tarceva R[package insert]. Roche Pharma (Schweiz) Ltd. Schoenmattstrasse 2 4153 Reinach. Switzerland. Available from: http:// www.roche.co.kr./fmfiles/re7198001/product/insertpaper/Tarreva tab.pdf. |
9 | Hidalgo M, Bloedow D. Pharmacokinetics and Pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva). Semin Oncol 2003;30(3 Suppl 7):S25-S33. |
10 | Smith J. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clin Ther 2005;27: 1513-1534. DOI ScienceOn |
11 | Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552. DOI ScienceOn |
12 | Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. DOI ScienceOn |
13 | Yildirim Y, Ozyilkan O, Akcali Z, Basturk B. Drug interation between capecitabine and warfarin: a case report and review of the literature. Int J Clin Pharmacol Ther 2006;44:80-82. DOI |
14 | Francis CW. Prevention of venous thromboembolism in hospitalized patients with cancer. J Clin Oncol 2009;27:4874- 4680. DOI ScienceOn |
15 | Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003;41:1633-1652. DOI ScienceOn |
16 | Kolesar JM, Johnson CL, Freeberg BL, Berlin JD, Schiller JH. Warfarin-5-FU interaction: a consecutive case series. Pharmacotherapy 1999;19:1445-1449. DOI ScienceOn |
17 | Moretti LV, Montalvo RO. Elevated internationl normalized ratio associated with concurrent use of sorafenib and warfarin. Am J Health Syst Pharm 2009;66:2123-2125. DOI ScienceOn |
18 | Naranjo CA, Shear NH, Lanctot KL. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol 1992;32:897-909. DOI |
19 | Cohen MH, Williams GA, Sridhara R, et al. United States food and drug administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-1218. DOI ScienceOn |